Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 16/20 | 0.51 |
| ▸ | CCNK | O75909 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.48 |
| ▸ | CCR7 | P32248 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
| ▸ | F13A1 | P00488 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | TGM1 | P22735 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26526137 | 0.97 | CCR6 (0.49) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL25082879 | 0.91 | CCR6 (0.45) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL26461000 | 0.88 | CCR6 (0.67) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL30284864 | 0.88 | CCR6 (0.67) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL30201842 | 0.83 | CCR6 (0.56) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL26094659 | 0.83 | CCR6 (0.56) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL30284901 | 0.83 | CCR6 (0.62) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL26461008 | 0.83 | CCR6 (0.62) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL26523978 | 0.83 | CCR6 (0.51) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL30202156 | 0.83 | CCR6 (0.53) | CCR6CCNKCCNA2CDK2CDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133406-A1 | Aryl Sulfonyl (Hydroxy) Piperidines as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133406-A1 | Aryl Sulfonyl (Hydroxy) Piperidines as CCR6 Inhibitors | CCR6, CCR1, CCR4 | CCR6 1/4885CCNK 3333/4885CCNA2 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.